Cargando…
Novel homozygous CD46 variant with C‐isoform expression affects C3b inactivation in atypical hemolytic uremic syndrome
Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy that may lead to organ failure. Dysregulation of the complement system can cause aHUS, and various disease‐related variants in the complement regulatory protein CD46 are described. We here report a pediatric patient with aHUS...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804674/ https://www.ncbi.nlm.nih.gov/pubmed/35987516 http://dx.doi.org/10.1002/eji.202249838 |
_version_ | 1784862163786006528 |
---|---|
author | Schack, Vivien R. Herlin, Morten K. Pedersen, Henrik Jensen, J. Magnus Bernth Færch, Mia Bundgaard, Bettina Jensen, Rasmus K. Jensen, Uffe B. Christensen, Rikke Andersen, Gregers R. Thiel, Steffen Höllsberg, Per |
author_facet | Schack, Vivien R. Herlin, Morten K. Pedersen, Henrik Jensen, J. Magnus Bernth Færch, Mia Bundgaard, Bettina Jensen, Rasmus K. Jensen, Uffe B. Christensen, Rikke Andersen, Gregers R. Thiel, Steffen Höllsberg, Per |
author_sort | Schack, Vivien R. |
collection | PubMed |
description | Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy that may lead to organ failure. Dysregulation of the complement system can cause aHUS, and various disease‐related variants in the complement regulatory protein CD46 are described. We here report a pediatric patient with aHUS carrying a hitherto unreported homozygous variant in CD46 (NM_172359.3:c.602C>T p.(Ser201Leu)). In our functional analyses, this variant caused complement dysregulation through three separate mechanisms. First, CD46 surface expression on the patient's blood cells was significantly reduced. Second, stably expressing CD46(Ser201Leu) cells bound markedly less to patterns of C3b than CD46 WT cells. Third, the patient predominantly expressed the rare isoforms of CD46 (C dominated) instead of the more common isoforms (BC dominated). Using BC1 and C1 expressing cell lines, we found that the C1 isoform bound markedly less C3b than the BC1 isoform. These results highlight the coexistence of multiple mechanisms that may act synergistically to disrupt CD46 function during aHUS development. |
format | Online Article Text |
id | pubmed-9804674 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98046742023-01-06 Novel homozygous CD46 variant with C‐isoform expression affects C3b inactivation in atypical hemolytic uremic syndrome Schack, Vivien R. Herlin, Morten K. Pedersen, Henrik Jensen, J. Magnus Bernth Færch, Mia Bundgaard, Bettina Jensen, Rasmus K. Jensen, Uffe B. Christensen, Rikke Andersen, Gregers R. Thiel, Steffen Höllsberg, Per Eur J Immunol Immunodeficiencies and autoimmunity Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy that may lead to organ failure. Dysregulation of the complement system can cause aHUS, and various disease‐related variants in the complement regulatory protein CD46 are described. We here report a pediatric patient with aHUS carrying a hitherto unreported homozygous variant in CD46 (NM_172359.3:c.602C>T p.(Ser201Leu)). In our functional analyses, this variant caused complement dysregulation through three separate mechanisms. First, CD46 surface expression on the patient's blood cells was significantly reduced. Second, stably expressing CD46(Ser201Leu) cells bound markedly less to patterns of C3b than CD46 WT cells. Third, the patient predominantly expressed the rare isoforms of CD46 (C dominated) instead of the more common isoforms (BC dominated). Using BC1 and C1 expressing cell lines, we found that the C1 isoform bound markedly less C3b than the BC1 isoform. These results highlight the coexistence of multiple mechanisms that may act synergistically to disrupt CD46 function during aHUS development. John Wiley and Sons Inc. 2022-08-31 2022-10 /pmc/articles/PMC9804674/ /pubmed/35987516 http://dx.doi.org/10.1002/eji.202249838 Text en © 2022 The Authors. European Journal of Immunology published by Wiley‐VCH GmbH. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Immunodeficiencies and autoimmunity Schack, Vivien R. Herlin, Morten K. Pedersen, Henrik Jensen, J. Magnus Bernth Færch, Mia Bundgaard, Bettina Jensen, Rasmus K. Jensen, Uffe B. Christensen, Rikke Andersen, Gregers R. Thiel, Steffen Höllsberg, Per Novel homozygous CD46 variant with C‐isoform expression affects C3b inactivation in atypical hemolytic uremic syndrome |
title | Novel homozygous CD46 variant with C‐isoform expression affects C3b inactivation in atypical hemolytic uremic syndrome |
title_full | Novel homozygous CD46 variant with C‐isoform expression affects C3b inactivation in atypical hemolytic uremic syndrome |
title_fullStr | Novel homozygous CD46 variant with C‐isoform expression affects C3b inactivation in atypical hemolytic uremic syndrome |
title_full_unstemmed | Novel homozygous CD46 variant with C‐isoform expression affects C3b inactivation in atypical hemolytic uremic syndrome |
title_short | Novel homozygous CD46 variant with C‐isoform expression affects C3b inactivation in atypical hemolytic uremic syndrome |
title_sort | novel homozygous cd46 variant with c‐isoform expression affects c3b inactivation in atypical hemolytic uremic syndrome |
topic | Immunodeficiencies and autoimmunity |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804674/ https://www.ncbi.nlm.nih.gov/pubmed/35987516 http://dx.doi.org/10.1002/eji.202249838 |
work_keys_str_mv | AT schackvivienr novelhomozygouscd46variantwithcisoformexpressionaffectsc3binactivationinatypicalhemolyticuremicsyndrome AT herlinmortenk novelhomozygouscd46variantwithcisoformexpressionaffectsc3binactivationinatypicalhemolyticuremicsyndrome AT pedersenhenrik novelhomozygouscd46variantwithcisoformexpressionaffectsc3binactivationinatypicalhemolyticuremicsyndrome AT jensenjmagnusbernth novelhomozygouscd46variantwithcisoformexpressionaffectsc3binactivationinatypicalhemolyticuremicsyndrome AT færchmia novelhomozygouscd46variantwithcisoformexpressionaffectsc3binactivationinatypicalhemolyticuremicsyndrome AT bundgaardbettina novelhomozygouscd46variantwithcisoformexpressionaffectsc3binactivationinatypicalhemolyticuremicsyndrome AT jensenrasmusk novelhomozygouscd46variantwithcisoformexpressionaffectsc3binactivationinatypicalhemolyticuremicsyndrome AT jensenuffeb novelhomozygouscd46variantwithcisoformexpressionaffectsc3binactivationinatypicalhemolyticuremicsyndrome AT christensenrikke novelhomozygouscd46variantwithcisoformexpressionaffectsc3binactivationinatypicalhemolyticuremicsyndrome AT andersengregersr novelhomozygouscd46variantwithcisoformexpressionaffectsc3binactivationinatypicalhemolyticuremicsyndrome AT thielsteffen novelhomozygouscd46variantwithcisoformexpressionaffectsc3binactivationinatypicalhemolyticuremicsyndrome AT hollsbergper novelhomozygouscd46variantwithcisoformexpressionaffectsc3binactivationinatypicalhemolyticuremicsyndrome |